摘要
目的 明确喜炎平注射液治疗细菌性肠道感染的临床用药特征,为该药的临床使用提供参考。方法 选取2011年7月26日至2019年6月1日全国14家三甲医院临床信息系统中3 846例使用喜炎平注射液的细菌性肠道感染的患者,对临床一般用药记录信息、诊断方案信息、一般治疗信息及合并用药信息采用频数统计和关联规则分析方法进行分析。结果 患者年龄1~3岁最多(2 378例);男性患者多于女性。合并疾病类型分析中前3位包括其他形式心脏疾病、急性上呼吸道感染、代谢疾病。联合用药方面,联合西药类别以其他心脏病用药、肝素类药、第三代头孢菌素药、黏液溶解药、H2-受体拮抗药等为主;联合中药类别以清热剂、清热解毒剂为主。西药类别联合抗生素药物中最常见的是第三代头孢菌素、青霉素。结论 通过合并疾病和关联规则发现,细菌性肠道感染患者还可能会合并或继发其他心脏疾病和急性上呼吸道感染,临床应注意检查患者是否出现此类疾病;使用喜炎平注射液时要注意避免药物联合应用导致的不良反应。
Objective To find out about the clinical characteristics of Xiyanping injection in the treatment of bacterial intestinal infections in order to provide reference for its clinical use.Methods A total of 3846 patients with bacterial intestinal infections treated with Xiyanping injection were selected from clinical information systems of 14 big hospitals in China between July 26,2011 and June 1,2019.The records of clinical medications,diagnostic protocols,basic data on treatment and combined medications were analyzed using frequency statistics and association rules.Results Most of the patients were aged 1 to 3(2378 cases).Male patients outnumbered female ones.The top three comorbidities included other forms of heart disease,acute upper respiratory tract infections and metabolic disease.In terms of drug combinations,the main Western drugs were those for other forms of heart disease,heparin drugs,third-generation cephalosporins,mucolytic drugs and H2-receptor antagonists.Drug combinations with traditional Chinese medicine were dominated by heat-clearing agents.The third-generation cephalosporin and penicillin were the most common Western drugs combined with antibiotics.Conclusion Patients with bacterial intestinal infections may also be complicated with or vulnerable to secondary cardiac diseases and acute upper respiratory tract infections.It is critical to find out whether patients have such diseases.At the same time,clinicians should be alert to adverse reactions caused by Xiyanping injection when used in combination with other drugs.
作者
史卜文
李利寻
谢雁鸣
王志飞
王淇
SHI Bowen;LI Lixun;XIE Yanming;WANG Zhifei#;WANG Qi(Institute of Clinical Basic Medicine of Chinese Medicine,Beijing 100700,China;School of Statisitcs,Renmin University of China,Beijing 100872,China)
出处
《中国药物警戒》
2023年第9期1017-1021,1026,共6页
Chinese Journal of Pharmacovigilance
基金
国家自然科学基金资助项目(81973982)
国家重点研发计划(2018YFC1707400)。
关键词
真实世界
喜炎平
注射液
细菌性肠道感染
用药特征
real world
Xiyanping
injection
bacterial intestinal infection
drug characteristics